AC
NAMSW icon

Aristeia Capital’s NewAmsterdam Pharma Warrant NAMSW Stock Holding History

Aristeia Capital’s Portfolio NAMSW Stock Details NAMSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$343K Hold
15,708
– – 0.01% 422
2025
Q4 		$397K Buy
+15,708
New +$390K 0.01% 361

Other funds holding NAMSW

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VI
Vestcor Inc Fredericton, New Brunswick, Canada $3.63B AUM 21.49% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Aristeia Capital's NAMSW Position: Q1 2026 in Review

Aristeia Capital held its NewAmsterdam Pharma Warrant (NAMSW) position steady in Q1 2026 at 15,708 shares worth $343K. The position accounts for 0.01% of the portfolio, ranked #422.

Aristeia Capital first reported a position in NAMSW in Q4 2025 and has held it in 2 quarters since. The position peaked at $397K in Q4 2025. 9 funds tracked by Wall St. Rank hold NAMSW as of Q1 2026.

  • Aristeia Capital held 15,708 shares of NewAmsterdam Pharma Warrant worth $343K as of Q1 2026.
  • Aristeia Capital left its NewAmsterdam Pharma Warrant share count unchanged in Q1 2026.
  • NewAmsterdam Pharma Warrant made up 0.01% of Aristeia Capital's portfolio in Q1 2026, its #422 holding.
  • Aristeia Capital first reported a position in NewAmsterdam Pharma Warrant in Q4 2025 and has held it in 2 quarters since.
  • Aristeia Capital's NewAmsterdam Pharma Warrant position peaked at $397K in Q4 2025.
  • 9 funds tracked by Wall St. Rank held NewAmsterdam Pharma Warrant as of Q1 2026.

Based on Aristeia Capital's 13F filing for Q1 2026, filed 15 May 2026.